Home › Kanser sa Ovary › Indiana › Indianapolis
Pag-aaral pangklinika para sa Kanser sa Ovary sa Indianapolis, IN
Isang pag-aaral para sa Kanser sa Ovary ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Indianapolis. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Nagre-recruitPhase 1
- IU Simon Cancer Center, Indianapolis
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Nagre-recruitPhase 2
- Indiana University Melvin and Bren Simon Cancer Center /ID# 275492, Indianapolis
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Nagre-recruitPhase 2
- Site 0284 - Community Cancer Center North, Indianapolis
- Site 0217 - St Vincent Hospital and Health Care Centers, Indianapolis
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Nagre-recruitPhase 3
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Nagre-recruitPhase 1
- Indiana University (IU) School of Medicine, Indianapolis
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Nagre-recruitPhase 1/2
- Community Health Network, Indianapolis
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Nagre-recruitPhase 3
- Franciscan Health Indianapolis ( Site 0081), Indianapolis
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Nagre-recruitPhase 3
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Nagre-recruitPhase 1
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Nagre-recruitPhase 1/2
- Riley Hospital for Children, Indianapolis
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Nagre-recruitPhase 1
- Indiana University, Indianapolis
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Nagre-recruit
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Nagre-recruitPhase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
- at 1 pa
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Community Health Network, Indianapolis
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Nagre-recruitPhase 2/3
- Community Health Network - MD Anderson, Indianapolis
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Nagre-recruitPhase 1
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network Investigational Drug Services, Indianapolis
- at 1 pa
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Nagre-recruitPhase 3
- Indiana University, Indianapolis
Pag-aaral para sa Kanser sa Ovary sa ibang lungsod
- Houston, TX89 pag-aaral
- New York City, NY69 pag-aaral
- Boston, MA61 pag-aaral
- Los Angeles, CA50 pag-aaral
- Nashville, TN49 pag-aaral
- Arlington, VA46 pag-aaral
- Philadelphia, PA44 pag-aaral
- Columbus, OH39 pag-aaral
- St. Louis, MO38 pag-aaral
- Chicago, IL36 pag-aaral
- San Antonio, TX31 pag-aaral
- Cleveland, OH30 pag-aaral
Iba pang pag-aaral sa Indianapolis
- Non-Small Cell Lung Cancer32 pag-aaral
- Kanser (lahat ng uri)24 pag-aaral
- Pagkabigo ng Puso23 pag-aaral
- Obesity20 pag-aaral
- Kanser sa Suso20 pag-aaral
- Metastatic Cancer19 pag-aaral
- Colorectal Cancer18 pag-aaral
- Sakit sa Puso at Ugat ng Dugo17 pag-aaral
- Kanser sa Baga16 pag-aaral
- Type 1 Diabetes14 pag-aaral
- Kanser ng Endometrium14 pag-aaral
- Sakit ni Alzheimer14 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.